摘要
AbstractThis study aimed to estimate the risk of venous thromboembolism (VTE), arterial thromboembolism (ATE), and other side effects following the use of drospirenone (DRSP)-containing combined oral contraceptives (COCs). When compared with non-DRSP-containing COCs, DRSP-containing COCs decreased the risk of VTE by 15% in the overall study population, although this was not statistically significant (adjusted hazard ratio/risk ratio [95% confidence interval] 0.85 [0.69, 1.04]). DRSP-containing COCs also showed significant benefits in terms of ATE risk. The body mass index of the subjects significantly decreased by 0.64 kg/m2 after taking the DRSP-containing COCs for 6 months. We concluded that DRSP-containing COCs were safe for use and could be broadly recommended.
机构地区
Reproductive Medical Center, Department of Obstetrics and Gynecology, Tangdu Hospital, the Airforce Military Medical University, Xi’an 710038, China,Department of Obstetrics and Gynecology, Peking University International Hospital, Beijing 102206, China,Bothwin Clinical Study Consultant, Redmond, WA
出版日期
2021年10月10日（中国期刊网平台首次上网日期，不代表论文的发表时间）
